.png)
SummaryVAT on medicines is a national decision, and the spread across Europe is wide: France applies 2.1 percent, Cyprus 5 percent, Estonia and the Netherlands 9 percent, Italy 10 percent, Finland 13.5 percent. Several countries apply their standard rate instead. For anyone comparing prices across borders this is not a detail. Six European countries publish consumer prices that include VAT, so a raw comparison of those figures measures tax policy as much as medicine pricing.
VAT is the last element added before the patient or payer pays. The chain runs ex-factory price, wholesale margin, pharmacy purchase price, pharmacy margin, retail price, then VAT on top. Two consequences follow:
Get the rate wrong and every subsequent step inherits the error, because the margin scales are applied to the net figures.
The following rates come from our own recalculation against the national authority files, not from secondary summaries. Each was checked on 3 September 2026.
| Country | VAT on medicines | How it was verified |
|---|---|---|
| France | 2.1 percent | Applied in the back calculation from the BDPM consumer price |
| Cyprus | 5 percent | Applied in the band based back calculation of the Ministry of Health price list |
| Estonia | 9 percent | Applied to the Tervisekassa consumer price |
| Netherlands | 9 percent | Applied to the G-Standaard consumer price |
| Italy | 10 percent | Applied to the AIFA Classe A retail price |
| Finland | 13.5 percent | Named in the authority file itself, recalculated across 5,945 rows |
Finland is the instructive case. The rate changed on 1 January 2026, and at the time of our check the consolidated version of the relevant law still showed the older schedule while the authority file already carried the new rate. Where the two disagree, the file that carries the prices is the one to follow, and the discrepancy belongs in your documentation.
Because we have not verified the remaining rates ourselves, and a pricing decision should not rest on a number copied from a commercial summary. The rates above are the ones that appear in our own conversion rules, each tied to a national source and an effective date.
For the remaining countries, two authoritative routes exist. The European Commission maintains the Taxes in Europe Database, which lists rates by country and by category of goods, and publishes an overview of VAT rates in the member states. Both were reachable on 14 September 2026. The national tax authority remains the primary source, and for a specific pack the price file of the national medicines authority is usually the fastest confirmation, because the rate is implicit in the published gross price.
Under the EU VAT Directive, member states may apply reduced rates to categories listed in Annex III, and pharmaceutical products are one of those categories. That is why rates on medicines are frequently well below the standard rate, and why they differ so much: the directive permits the reduction, it does not prescribe a level. Some member states apply a super reduced rate to medicines, others only a reduced rate, and a few apply the standard rate to parts of the pharmacy assortment.
Two practical implications follow. First, the rate can differ within a country between prescription medicines, over the counter products and other pharmacy goods, so the category matters as much as the country. Second, rates change with national budget decisions, and the change takes effect on a date that your dataset has to carry.
France publishes a gross consumer price in its public database, and the route down to the manufacturer level shows why the rate has to come first.
Two warnings belong with that sequence. The French margin formula changes on 20 January 2027, so any stored back calculation needs a version and a validity date. And the French public database carries a price for 13,648 of 20,900 packs, because non reimbursed products are not listed, so the result covers two thirds of the national universe rather than all of it.
External reference pricing compares countries at a defined level, and the baskets mix countries that publish gross prices with countries that publish net ones. The Dutch maximum price calculation, for example, reads Belgium, France, Norway and the United Kingdom. Belgium publishes ex-factory, France publishes a gross consumer price, and Norway publishes pharmacy purchase prices.
A basket calculation therefore has to normalise before it compares, and VAT removal is the first normalisation step for the gross members of the basket. Where an analyst skips it, the gross country looks systematically expensive and can never become the reference, which quietly changes the result of the whole calculation.
The same applies in the other direction. A country that lowers VAT on medicines lowers its published gross price without any change in the manufacturer price, and every formula that reads that country at gross level sees a price cut that did not happen commercially.
One: comparing a gross price with a net price. France, Spain, Portugal, Estonia, Cyprus and the Netherlands publish consumer prices. Germany, Belgium and Poland publish net figures at manufacturer level. A direct comparison of the two groups measures the tax system before it measures anything else.
Two: applying the rate at the wrong point. VAT is removed first, before the margin scales, because the scales are defined on net values. Removing it after a margin scale produces a number that is close enough to look right and wrong on every pack.
Three: using an outdated rate. Finland's change on 1 January 2026 is the current example. Any dataset that carries a VAT rate should carry its effective date next to it.
Three other effects reduce or change a published price, and none of them is a tax.
Keeping these apart in the data model matters, because each has a different owner, a different update rhythm and a different legal basis. A single field called discount collapses all three and makes the dataset unusable for audit.
VAT on medicines ranges from 2.1 percent in France to double digit rates elsewhere, and six European countries fold it into the prices they publish. The rate is not a nuisance parameter: it decides whether two national prices are comparable at all. Verify it at the source, record it with an effective date, and remove it before anything else in a back calculation.
Related reading: European Drug Pricing Database: how cross-border prices work and Pharma pricing Germany: how the system works, plus wholesale and pharmacy margins.
pharmazie.com is the consolidated pharmaceutical data platform by DACON Datenbank Consulting GmbH that bundles 25+ specialist databases into a single search, exclusively for healthcare professionals. Price coverage focuses on the DACH region and a number of further EU countries, with more countries following in the coming months.
